Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
Introduction
Rheumatoid arthritis (RA) has long been considered a systemic disease with extra-articular involvement including interstitial lung disease (ILD) [1]. Biologics and non-biological disease-modifying antirheumatic drugs (nbDMARDs) are the mainstay in the management of RA. Their symptomatic and structural efficacy is well established. On the other hand, especially since the advent of biologics, several observations have stressed certain adverse effects, some of them potentially life-threatening such as infections and malignancy [2], [3].
With regard to pulmonary toxicity, drug-induced ILD has been reported in the past as a rare but severe adverse event with almost all nbDMARDs, such as gold [4] and methotrexate (MTX) [5], and clinicians are usually aware of MTX-induced pneumonitis. By analogy, other nbDMARDs, such as leflunomide (LEF), and biologics were subsequently suspected to induce lung injury given that unexpected multiple cases of new-onset or exacerbation of ILD have been reported in association with almost every RA treatment. We decided to undertake a systematic literature research (SLR) in order to better characterize the magnitude of this problem.
Section snippets
Data sources and searches
We performed a systematic review [6] of articles published from 1975 to July 2013, restricted to English and French languages and to human adults, in Medline (via PubMed), Cochrane, and Embase databases, as well as abstracts presented at the American College of Rheumatology (ACR) 2010–2012 and European League Against Rheumatism (EULAR) 2010–2013 annual meetings, with the help of an experienced librarian. We also hand searched for relevant additional references. Main search terms were
Results
A total of 910 references were identified through database searching (Fig.). An additional 43 references from conference abstracts and hand-search screening were found. Of the 786 references screened after removing duplicates, the first step of the systematic review excluded 619 references that were not relevant to our topic. Of the remaining 167 references, 137 were selected for full-text review. Finally, 88 full case reports or series were selected for qualitative analysis. The other 49
Methotrexate
MTX-induced ILD is the prototype of drug-induced lung toxicity in RA patients. MTX-induced lung toxicity was first described in children treated for leukemia in 1969 [94], and later, in 1983, low doses of MTX were reported to induce pneumonitis in RA patients [7]. Acute pneumonitis can occur at any time during MTX therapy; its exact incidence is difficult to assess, but it is estimated to be between 0.3% and 8% of patients receiving MTX for rheumatic disorders including RA [28]. In a SLR of 88
Conclusion
Based on the recent multiple case reports and reviews, there was a general impression of increased pulmonary toxicity induced by the biologics and especially the TNFi, alone or in combination with MTX. However, this adverse effect, even potentially fatal, seems to be relatively rare based on this literature review. For MTX or LEF or TNFi, the estimated prevalence of possible induced ILD is around 1%. For comparison, estimates of the prevalence of ILD in RA range widely between 1% and 58% [135],
Acknowledgment
The authors are grateful to Virginia Wallis for her assistance with the manuscript preparation.
References (139)
- et al.
Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate
Semin Arthritis Rheum
(1987) - et al.
Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings
Chest
(1993) - et al.
Pulmonary function in patients receiving long-term low-dose methotrexate
Chest
(1996) - et al.
A case of acute pneumonitis associated with leflunomide treatment
Respiry Med Extra
(2005) - et al.
An elderly man with rheumatoid arthritis and dyspnea
Chest
(2009) - et al.
Sulfasalazine-induced pulmonary disease
Chest
(1992) - et al.
Acute organizing interstitial pneumonia and interstitial nephritis due to salazosulfapyridine in a patient with rheumatoid arthritis
Allergol Int
(2003) - et al.
Exacerbation of interstitial lung disease during etanercept therapy: two cases
Joint Bone Spine
(2008) - et al.
Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition
Chest
(2002) - et al.
Organizing pneumonia after rituximab therapy: two cases
Joint Bone Spine
(2008)